Tarsons Products Limited — PPTs, 13-11-2025: Investor Presentation

Tarsons Products' H1FY26 results show a mixed bag for investors. Consolidated revenue grew 5.2% YoY to ₹193.7 Cr, with EBITDA up a strong 18.4% to ₹52.1 Cr, boosting margins by 300 bps. However, Profit After Tax (PAT) dipped sharply by 64% to ₹5.1 Cr. This PAT decline is due to higher depreciation and finance costs from new manufacturing facilities in Panchla and Amta, which are now capitalized but not yet generating full revenue.

The silver lining? Cash PAT surged 20.8% to ₹47.5 Cr, showing strong operational cash flow. Management expects these new facilities to ramp up swiftly from FY27, driving future revenue growth and margin expansion. Tarsons is aggressively expanding capacity, introducing new products like cell culture labware, and pushing into overseas markets, including via its Nerbe acquisition. They're investing now for sustainable growth over the next 3-5 years, leveraging automation and a robust pan-India & global distribution network.